| N-((1S)-1-{[4-((2S)-2-{[(2, 4-dichlorophenyl) sulfonyl] amino}-3-hydroxypropanoyl)-1-piperazinyl] carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel … KS Thorneloe, AC Sulpizio, Z Lin, DJ Figueroa, AK Clouse, GP McCafferty, ... Journal of Pharmacology and Experimental Therapeutics 326 (2), 432-442, 2008 | 418 | 2008 |
| Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine JA Feild, L Zhang, KA Brun, DP Brooks, RM Edwards Biochemical and biophysical research communications 258 (3), 578-582, 1999 | 232 | 1999 |
| Pharmacology of synthetic organic selenium compounds MJ Parnham, E Graf, VM Kolb, R Seth, S Sinha, RR Ruffolo, JP Hieble, ... Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des …, 1991 | 231 | 1991 |
| Antioxidant activity of carvedilol in cardiovascular disease P Dandona, H Ghanim, DP Brooks Journal of hypertension 25 (4), 731-741, 2007 | 226 | 2007 |
| Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis ET Grygielko, WM Martin, C Tweed, P Thornton, J Harling, DP Brooks, ... Journal of Pharmacology and Experimental Therapeutics 313 (3), 943-951, 2005 | 220 | 2005 |
| Sex difference in the development of deoxycorticosterone-salt hypertension in the rat. Y Ouchi, L Share, JT Crofton, K Iitake, DP Brooks Hypertension 9 (2), 172-177, 1987 | 174 | 1987 |
| Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in … EH Ohlstein, DP Brooks, GZ Feuerstein, RR Ruffolo Jr Pharmacology 55 (5), 244-251, 1997 | 160 | 1997 |
| Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase–dependent in a rat model of cardiac hypertrophy and dysfunction TM Behr, SS Nerurkar, AH Nelson, RW Coatney, TN Woods, A Sulpizio, ... Circulation 104 (11), 1292-1298, 2001 | 145 | 2001 |
| Central adrenergic control of vasopressin release DP Brooks, L Share, JT Crofton Neuroendocrinology 42 (5), 416-420, 1986 | 134 | 1986 |
| Molecular mechanisms of antidiuretic effect of oxytocin C Li, W Wang, SN Summer, TD Westfall, DP Brooks, S Falk, RW Schrier Journal of the American Society of Nephrology 19 (2), 225-232, 2008 | 128 | 2008 |
| Vasopressin release in male and female rats: effects of gonadectomy and treatment with gonadal steroid hormones JT CROFTON, PG BAER, L SHARE, DP BROOKS Endocrinology 117 (3), 1195-1200, 1985 | 120 | 1985 |
| Upregulation of renal endothelin receptors in rats with cyclosporine A-induced nephrotoxicity P Nambi, M Pullen, LC Contino, DP Brooks European journal of pharmacology 187 (1), 113-116, 1990 | 118 | 1990 |
| Vasopressin in rats with genetic and streptozocin-induced diabetes DP Brooks, DF Nutting, JT Crofton, L Share Diabetes 38 (1), 54-57, 1989 | 109 | 1989 |
| Nonpeptide endothelin receptor antagonists. V: Prevention and reversal of acute renal failure in the rat by SB 209670. M Gellai, M Jugus, T Fletcher, P Nambi, EH Ohlstein, JD Elliott, DP Brooks Journal of Pharmacology and Experimental Therapeutics 275 (1), 200-206, 1995 | 107 | 1995 |
| Characterization of canine renal endothelin receptor subtypes and their function. DP Brooks, PD DePALMA, M Pullen, P Nambi Journal of Pharmacology and Experimental Therapeutics 268 (3), 1091-1097, 1994 | 99 | 1994 |
| Central atrial natriuretic factor reduces vasopressin secretion in the rat K Iitake, L Share, JT Crofton, DP Brooks, Y Ouchi, EH Blaine Endocrinology 119 (1), 438-440, 1986 | 99 | 1986 |
| The discovery of GSK221149A: a potent and selective oxytocin antagonist J Liddle, MJ Allen, AD Borthwick, DP Brooks, DE Davies, RM Edwards, ... Bioorganic & medicinal chemistry letters 18 (1), 90-94, 2008 | 98 | 2008 |
| Carvedilol: a novel cardiovascular drug with multiple actions RR Ruffolo Jr, DA Boyle, DP Brooks, GZ Feuerstein, RP Venuti, MA Lukas, ... Cardiovascular drug reviews 10 (2), 127-157, 1992 | 98 | 1992 |
| Sgk, a putative serine/threonine kinase, is differentially expressed in the kidney of diabetic mice and humans JM Kumar, DP Brooks, BA Olson, NJ Laping Journal of the American Society of Nephrology 10 (12), 2488-2494, 1999 | 97 | 1999 |
| Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator H Zeng, IM Lozinskaya, Z Lin, RN Willette, DP Brooks, X Xu Journal of Pharmacology and Experimental Therapeutics 319 (2), 957-962, 2006 | 94 | 2006 |
